ClearPoint Neuro, Inc. reported $42M of revenue over the trailing twelve months, +26% on the year before. 10 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $42M (to Q2 2026). Net income: −$35M, trailing twelve months to Q2 2026. Free cash flow: −$31M, trailing twelve months to Q2 2026. Operating margin: −73%, trailing twelve months to Q2 2026.

CLPTClearPoint Neuro, Inc.

Healthcare

$10.48-60% 1Y

$10.48

$8.6652 weeks$29.60

CLPT as reported

ClearPoint Neuro, Inc. reported $42M of revenue over the trailing twelve months, +26% on the year before. 10 reported series are charted on this page, each one as filed.

$42M

Revenue, trailing twelve months · to Q2 2026 · +26% against the twelve months before

Net income: −$35M
Net income · +56% year on year · trailing twelve months to Q2 2026
Free cash flow: −$31M
Free cash flow · +167% year on year · trailing twelve months to Q2 2026
Operating margin: −73%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for CLPT, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$42M	+26%	Q2 2026
Net income	−$35M	+56%	Q2 2026
EPS	−$1.18	+46%	Q2 2026
Gross margin	63%	n/a	Q2 2026
Operating margin	−73%	n/a	Q2 2026
Net margin	−81%	n/a	Q2 2026
ROE	−178%	n/a	Q2 2026
ROA	−34%	n/a	Q2 2026
ROIC	−116%	n/a	Q2 2026
Free cash flow	−$31M	+167%	Q2 2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.